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Poster Session I S213Current management strategies are suboptimal and associated with
significant adverse effects. Patients undergoing alloSCT are pro-
foundly immunocompromised and do not respond to vaccination
with CMV antigens. Immunotherapy (IT) with CMV specific do-
nor-derived cytotoxic T lymphocytes (CTL) is effective after al-
loSCT, but is expensive, labor intensive, and difficult to replicate.
Non-toxic strategies are needed to improve outcomes. In earlier
studies, we showed that ex vivo expanded activated T cells (ATC)
armed with anti-CD3 anti-Her2/neu bispecific antibody (Her2Bi)
exhibit high levels of specific cytotoxicity directed at breast cancer
cell lines. Using this strategy, we tested ATC armed with anti-
CD3 (OKT3)  anti-CMV (Cytogam) bispecific antibodies
(CMVBi) to target and lyse CMV-infected fibroblasts. Normal do-
nor ATC were generated and armed with CMVBi. Specific cytotox-
icity was tested by 51Cr release using CMV-infected or uninfected
human fibroblasts. CMVBi alone, CMVBi-armed ATC (aATC),
and ATC alone were tested for their ability to kill. ATC were armed
with 0.001 to 500 ng of CMVBi/106ATC at effector:target (E:T)
from 3.125:1 to 25:1. IFNgEliSpot was used to assess IFNg secreting
cells in ATC and aATC after exposure to CMV-infected and unin-
fected fibroblasts. ATC armed with CMVBi as little as 0.001 ng/
106 ATC was significantly more cytotoxic than unarmed ATC.
There was higher cytotoxicity mediated by aATC as the multiplicity
of infection (MOI) increased in target cells. At all E:T, CMVBi arm-
ing at a dose of 50 ng/106 ATC exhibited dramatically higher lysis of
CMV-infected targets (MOI 1) than that exhibited by ATC alone.
Cytotoxicity mediated by unarmed and armed ATCwas background
in uninfected targets. Immunofluorescent studies showed that aATC
aggregated around GFP fluorescence-marked CMV-infected fibro-
blasts. Cytokine secretion analyzed by IFNg EliSpot confirmed im-
mune responses. The lack of MHC restriction in the mediation of
cytotoxicity, polyclonal targeting of multiple CMV antigens and
the simplicity of expanding donor T cells makes it easy to adapt
this effective strategy against CMV infection post alloSCT.162
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Adoptive transfer of virus-specific T cells can effectively restore
antiviral immunity after stem cell transplantation. However, proto-
cols for eliciting virus-specific T cells from existing memory T cells
of CMV-seropositive adult (CMVpos) donors have been ineffective
when applied to na€ıve cord blood (CB) transplant (CBT) recipients
due to absence of antigen-specific memory cells in these grafts.
We previously demonstrated that CMVpp65-specific T cells could
be generated from CB using a modified protocol and that 15/15
CB T cell lines recognized atypical epitopes of pp65. To test if na€ıve
T cells from CMV-seronegative donors (CMVnegs) also recognize
atypical epitopes, we again optimized our previous method.
CD45RA1 na€ıve T cells were selected from peripheral blood and
stimulated with pp65-pepmix-pulsed DC with IL7, IL12, and
IL15. For subsequent stimulations T cells were stimulated with
pp65-pepmix-pulsed EBV-LCL and IL15 or IL2. CMVpp65-spe-
cific T cells (CMV-CTL) expanded from 8 of 11 CMVnegs and
were primarily CD81 T cells (mean 71%). These T cells secreted
markedly more IFN-g in response to pp65 peptides (mean 224;
range: 38-611 SFC/1x105 cells) than to irrelevant peptides (mean
12;Range 3-37) as measured in Elispot assays. These T cells lysed
pp65-pulsed target cells (mean:48;Range:15-70%) but not negative
controls (mean 22;Range 4-40%) in cytotoxicity assays. As with
CB, CMVneg CMV-CTL were derived from na€ıve T cells and rec-
ognized only atypical pp65 epitopes. These findings raised the con-
cern that the viral epitopes presented by endothelial cells infectedwith CMV in patients might not present the atypical peptides recog-
nized by our CMV-CTL. We hypothesized that the epitopes pre-
sented to T cells by endothelial cells or other APCs after CMV
infection are different to those presented in our in vitro system.
We tested if different epitopes would dominate the na€ıve T cell re-
sponse to CMV AD169-infected fibroblasts and CMV VR1814-in-
fected DC. The responding na€ıve T cells were again specific for
atypical epitopes showing that these epitopes were indeed presented
by cells naturally infected with CMV. This reassured us that despite
their unusual repertoire, T cells derived from CB or CMVnegs
should control CMV infections.We are now evaluating their clinical
efficacy in recipients of CBT and soon Hematopoietic Stem Cell
Transplantation. These studies should determine if na€ıve T cells
primed in vitro are able to persist and establish memory in vivo.163
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First generation chimeric antigen receptors (CAR) usually combine
the antigenbindingdomainof amonoclonal antibodywith the z signal-
ing domain of theT cell receptor/CD3 complex.When expressed inT
cells, thoseCARprovide potent antigen-specific, nonMHC-restricted
effector function against tumor cells in vitro, but clinical trials have
shown limited expansion and persistence of these lymphocytes in
vivo. This limitation is likely attributable to the failure of these CAR
to fully activate T cells following target antigen engagement on tumor
cells, since tumors lack expression of costimulatorymolecules required
for sustainedT cell activation. Incorporation of costimulatory endodo-
mainswithin theCAR, such asCD28, increases proliferation and activ-
ity of themodifiedT cells in vitro andmay enhance their benefit in vivo
but, as yet, the relevanceand valueof thesemodifications inhumansub-
jects remains speculative.
We now present results from a phase I trial of T cells redirected to
CD19 given to patients with refractory/relapsed B-cell malignancies.
Patients were simultaneously infused with 2 autologous T cell prod-
ucts expressing CAR with identical CD19-specific exodomains. In
one product, the endodomain contained only the z sequence
(CAR.19z) while, in the second product, we added a costimulatory
CD28 domain (CAR.19-28z). We could thus directly measure and
compare the expansion, persistence and effectiveness of each cell
population in every patient. Six subjects have been treated at 3 cell
dose levels (Table). Persistence of CAR1 T cells was assessed in
blood by Q-PCR assays specific for each population.
Table 1. Characteristics of the infused CD19-redirected




(20:1 E:T ratio)CAR.19z T cells 44 ± 23 49 ± 22 6 ± 5 50 ± 24 53 ± 10CAR.18-28z T cells 47 ± 26 48 ± 22 6 ± 6 47 ± 66 65 ± 19All numbers are shown as mean percentage6 standard deviation. T cell
products were generated by activation of autologous peripheral blood
mononuclear cells with immobilized OKT3, gene modification with ret-
roviral vectors encoding either CAR.19z or CAR.19-28z and ex vivo ex-
pansion for a median of 14 days (range 6-18) in the presence of IL-2.
Three dose levels have been administered: 2107, 1108 and 2108
cells of each product/m2.
All infusions were well tolerated. CAR.19-28z cells were detected at
a low level after infusion, but progressively increased 7- to 63-fold,
peaking at 1-2 wk, before declining to background levels over the
